MARKET

TTPH

TTPH

Tetraphase
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.370
-0.270
-16.46%
Opening 13:12 03/31 EDT
OPEN
1.650
PREV CLOSE
1.640
HIGH
1.750
LOW
1.320
VOLUME
236.63K
TURNOVER
--
52 WEEK HIGH
27.40
52 WEEK LOW
0.5600
MARKET CAP
9.95M
P/E (TTM)
-0.0561
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TTPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TTPH stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.

EPS

TTPH News

More
  • OMI, PSTV, GRPN and WMC among midday movers
  • Seeking Alpha - Article · 1d ago
  • Acelrx Pharmaceuticals: A New Chapter
  • Seeking Alpha - Article · 6d ago
  • TTPH, TCO, LM, and WLTW SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
  • GlobeNewswire · 03/24 16:36
  • SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - WLTW, TTPH, TERP
  • ACCESSWIRE · 03/19 18:55

Industry

Pharmaceuticals
-0.38%
Pharmaceuticals & Medical Research
-0.69%

Hot Stocks

Symbol
Price
%Change

About TTPH

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
More

Webull offers kinds of Tetraphase Pharmaceuticals Inc stock information, including NASDAQ:TTPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTPH stock news, and many more online research tools to help you make informed decisions.